

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6514643

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	1
CONVEYING PARTY DATA	
Name	Execution Date
GARETH CHARLES GLYNDWR DAVIES	06/17/2019
RECEIVING PARTY DATA	
Name:	CELLTECH R&D LIMITED
Street Address:	208 BATH ROAD
City:	SLOUGH, BERKSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	SL1 3WE
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17253660
CORRESPONDENCE DATA	
Fax Number:	(352)372-5800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3523758100
Email:	fce@slepatents.com
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	JAK.109
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.
SIGNATURE:	/FRANK C. EISENSCHENK/
DATE SIGNED:	01/22/2021
Total Attachments: 6	
source=ExecAsgn-Davies#page1.tif	
source=ExecAsgn-Davies#page2.tif	
source=ExecAsgn-Davies#page3.tif	
source=ExecAsgn-Davies#page4.tif	
source=ExecAsgn-Davies#page5.tif	

THIS DEED is made the 17 day of June 2019

BETWEEN:-

(1) Gareth Charles Glyndwr DAVIES a British citizen; c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom (hereinafter called "the Inventor" which expression where the context so allows shall include his personal representatives and assigns);

(2) CELLTECH R&D LIMITED, a company incorporated under the laws of England and Wales and having its registered office at 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom (hereinafter called "Celltech R&D" which expression where the context so allows shall include its successors and assigns); and

(3) UCB BIOPHARMA SPRL, a Belgian body corporate, having its registered office at Allée de la Recherche 60, B-1070 Brussels, Belgium (hereinafter called "UCB Biopharma" which expression where the context so allows shall include its successors and assigns).

WHEREAS:-

(A) The Inventor claims to be an inventor of an invention relating to "GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER" ("the Invention") full particulars of which have been communicated by him to Celltech R&D and UCB Biopharma and which he is informed is or is intended to be the subject of one or more applications for patent protection filed in the name of UCB Biopharma initially as identified in Schedule 1 hereto and in respect of he has (as he hereby acknowledges) approved a specification as submitted to him by UCB Biopharma's Patent Attorneys.

(B) The Inventor made his contribution to the Invention while in the employment of Celltech R&D and in the course of his normal duties or in the course of duties falling outside his normal duties but specifically assigned to him and the circumstances were such that an invention might reasonably be expected to result from the carrying out of his duties and accordingly all his rights titles shares and interests in and to the Invention is to be taken (as between the Inventor and Celltech R&D) to belong to

Celltech R&D for the purposes of the Patents Act 1977 and for all other purposes of whatsoever nature.

(C) By reason of an Employee and IP Services Agreement dated 27 May 2005 between Celltech R&D and UCB S.A.; a Contribution of Assets made by UCB S.A. to UCB Pharma S.A. through a Notarial Deed dated 20 December 2006 and a Deed of Novation dated 20 December 2006 between Celltech R&D, UCB S.A. and UCB Pharma S.A.; and a Contribution of Assets made by UCB Pharma S.A. to UCB Biopharma through a Notarial Deed and its annexes dated 30 April 2014, it is agreed that all Celltech R&D's right title share and interest in and to the Invention including the full right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention in Europe and in all other countries of the world belongs to UCB Biopharma.

(D) The Inventor has agreed at the request of Celltech R&D and Celltech R&D has agreed at the request of UCB Biopharma to execute this Deed on the terms herein contained.

NOW THIS DEED WITNESSES as follows:

1. In pursuance of the said agreement and in consideration of the premises the Inventor and Celltech R&D HEREBY JOINTLY AND SEVERALLY and to the extent of their respective shares and interests therein ASSIGN and CONFIRM unto UCB Biopharma ALL THOSE their respective right title share and interest in and to the Invention and the patent application identified in Schedule 1 hereto and all patents granted thereon AND the full and exclusive benefit thereof TOGETHER WITH all rights of action and powers accruing or belonging to the Inventors or Celltech R&D AND the full right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention in Europe and in all other countries of the world including the benefit of any priority date and the right to make applications whether under any national law or under the International Convention for the Protection of Industrial Property or under any other applicable convention or treaty TO HOLD the same unto UCB Biopharma absolutely.

2. The Inventor and Celltech R&D HEREBY JOINTLY and SEVERALLY COVENANT and AGREE with UCB Biopharma as follows:-
(a) that he will at any time hereafter (whether or not the Inventor remains in the employ of Celltech R&D) and from time to time at the request of UCB Biopharma promptly execute and sign all such instruments applications and documents and do all such acts and things as may be

required by UCB Biopharma to enable UCB Biopharma to enjoy the full benefit of the rights hereby confirmed and assigned including applying for and obtaining a patent or patents or other similar forms of protection in respect of the Invention in Europe and in all other countries of the world and vesting the same in UCB Biopharma or its nominees when obtained;

(b) that he has not assigned or agreed to assign to any person firm or company other than UCB Biopharma or otherwise encumbered and will not hereafter assign or agree to assign to any person firm or company or otherwise encumber the Invention or the said patent applications or the right to apply for or obtain a patent or patents or other similar forms of protection in respect thereof in Europe or elsewhere throughout the world;

(c) that he will give to UCB Biopharma all such information in his possession or in his power relating to the Invention and the method of using or employing the same as UCB Biopharma shall require; and

(d) that he has not disclosed and will not hereafter disclose the Invention or any information whatsoever concerning the same to any person firm or company other than Celltech R&D, UCB Biopharma or UCB Biopharma's Patent Attorneys.

3. This document shall be governed by and construed in accordance with English Law.

IN WITNESS whereof this Instrument has been executed by the parties as a Deed in the presence of the persons mentioned below the day and year first before written.

SCHEDULE 1

<u>Patent Application</u>	<u>Application Number</u>	<u>Application Date</u>	<u>grant date or number</u>
United Kingdom	1809945.7	18 June 2018	
United Kingdom	1815694.3	26 September 2018	

SIGNED and DELIVERED as his Deed)

by the said Gareth Charles Glyndwr DAVIES)

in the presence of:-

) *G Davies*

.....

Witness Signature

Stumpius

Witness' Name

STAN HUNTERS

Address

10225 Bath Road

.....


SLUGBY, UK

Occupation


Administrator

SIGNED and DELIVERED as a Deed by
CELLTECH R&D LIMITED acting by
a Director in the presence of:-

)
) 
)
 **Yogesh Kumar**
Finance Director

Witness Signature 
Witness' name **SUMAN KUMARI**
Address **10 IPD, 208 Bath Road**
SUMAS, UK
Occupation **Adminstrator**

SIGNED and DELIVERED as a Deed by
UCB BIOPHARMA SPRL by a person
acting under the authority of such company
in accordance with the laws of the territory
in which it is incorporated

)
)
)
)
)


Title: Vice President
Head Group Intellectual Property